Do developers need a system for compensating research victims?; Eisai cites new round of positive Ph3 epilepsy data;

@FierceBiotech: New R&D culture at GSK forces a challenging showdown. News | Follow @FierceBiotech

@JohnCFierce: Argonne has begun construction of an advanced protein crystallization lab for drug research. Report | Follow @JohnCFierce

@RyanMFierce: Virtual drug discovery MT @BioWorld: "We're trying to digitalize biotech," says Zymeworks CEO after $187M deal with Merck Item | Follow @RyanMFierce

@MaureenFierce: Can targeted drugs save Big Pharma? Article May help wean Big Pharma off of big blockbusters. | Follow @MaureenFierce

> The subcommittee of a presidential bioethics commission believes that drug developers should have a system in place to compensate research victims. Many other countries require developers to carry insurance or have some other requirement to meet to ensure that any victims are properly compensated. In the U.S., anyone victimized by researchers can only hire an attorney and sue. Story

> The third in a string of three late-stage studies of Eisai's experimental epilepsy drug perampanel demonstrated positive results compared to a placebo. Investigators reported that 33.3% of patients taking an 8 mg dose of perampanel showed a reduction in seizure frequency of more than 50%. The rate was 33.9% for patients in the 12 mg arm and 14.7% for patients taking a placebo. Story

> Three North Carolina biotech upstarts each landed a $30,000 low-interest loan from the N.C. Biotech Center. Report

> Selecta Biosciences has won a contract from the SAIC to develop a new malaria vaccine using their nanoparticle technology. Release

Pharma News

@FiercePharma: Judge tosses all but one claim in Fosamax patient suit against Merck. No punitive damages allowed. News | Follow @FiercePharma

> Citi slashes Human Genome target on slow Benlysta sales. Report

> Crestor-Lipitor match-up results anticipated soon. More

> Valeant emerges as Afexas $76M white knight. Article

> European CMO snaps up Virginia Pfizer plant. Story

> Eye-sized Avastin doses caused blindness, FDA says. News

> Judge jettisons claims in bellwether Fosamax case. Details

Drug Delivery News

> FDA gives orphan OK to Pluristem's delivery platform for Buerger's disease. More

> Unilife aims prefilled syringes at patients who self inject. Story

> Newer drug-eluting stents reduce restenosis by 38%, thrombosis by half. Report

> MonoSol, KemPharmpartner on second ADHD thin-film drug. Details

> QLT reports successes with eye drug delivery, analyst skeptical. Article

> A more precise method of making micelles. News

Medical Device News

> Cardiox raises $8M in Series C. Report

> Lantos aims to help military, consumers with 3D ear-mapping. News

> S&N takeover rumors rekindled. Story

> B. Braun, CareFusion in patent disputes. Details

> Medtronic, NuVasive clash over patents. More

> GI dynamics raises $85 in Australian IPO. Article

And Finally... All the market turmoil this month scuttled 15 IPOs, making August the worst month for spiked IPOs since April, 2001. Report

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.